tienam 500 mg/500 mg prašek za raztopino za infundiranje
merck sharp & dohme, d.o.o. - cilastatin, imipenem - prašek za raztopino za infundiranje - cilastatin 500 mg / 1 viala; imipenem 500 mg / 1 viala - imipenem in cilastatin
rezolsta
janssen-cilag international n.v. - darunavir, cobicistat - okužbe z virusom hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - zdravilo rezolsta je indicirano v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje okužbe z virusom humane imunske pomanjkljivosti 1 (hiv 1) pri odraslih, starih 18 let ali več. genotipa testiranje mora vodnik za uporabo rezolsta.
ipratropijev bromid/salbutamol cipla 0,5 mg/2,5 mg v 2,5 ml inhalacijska raztopina za nebulator
cipla europe nv - salbutamol; ipatropijev bromid - inhalacijska raztopina za nebulator - salbutamol 2,5 mg / 2,5 ml ipatropijev bromid0,5 mg / 2,5 ml; ipatropijev bromid 0,5 mg / 2,5 ml - salbutamol in ipratropijev bromid
metalcaptase 150 mg gastrorezistentne tablete
sanolabor, d.d. - penicilamin - gastrorezistentna tableta - penicilamin 150 mg / 1 tableta - penicilamin
metalcaptase 150 mg gastrorezistentne tablete
penicilamin - gastrorezistentna tableta - penicilamin 150 mg / 1 tableta - penicilamin
doxy-100 gé 100 mg filmsko obložene tablete
kemofarmacija d.d. - doksiciklin - tableta - doksiciklin 100 mg / 1 tableta - doksiciklin
doxyderma 100 mg tablete
sanolabor, d.d. - doksiciklin - tableta - doksiciklin 100 mg / 1 tableta - doksiciklin
prezista
janssen-cilag international nv - darunavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.
ionsys
janssen-cilag international nv - fentanil hidroklorid - bolečina, postoperativna - analgetiki - zdravljenje akutne zmerne do hude pooperativne bolečine za uporabo v bolnišničnem okolju.
symtuza 800 mg/150 mg/200 mg/10 mg filmsko obložene tablete
janssen-cilag international nv - darunavir, emtricitabin, kobicistat, alafenamidtenofovirat - filmsko obložena tableta - darunavir 800 mg / 1 tableta; emtricitabin 200 mg / 1 tableta; kobicistat 150 mg / 1 tableta; alafenamidtenofovirat 10 mg / 1 tableta - -